HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 62: | Line 62: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| || | |[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||PENDING|| || || || ||FQR|| || | ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | |Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive | ||
|Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Jack Reid, MD (University of California, Irvine) Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| Line 69: | Line 69: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| | |[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Chronic Neutrophilic Leukemia (CNL) | |Chronic Neutrophilic Leukemia (CNL) | ||
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | |Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine <nowiki>**</nowiki>contributed equally | ||
| Line 76: | Line 77: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
| Line 83: | Line 85: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| | |[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Polycythemia Vera (PV) | |Polycythemia Vera (PV) | ||
|Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center | ||
| Line 90: | Line 93: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| | |[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Essential Thrombocythemia (ET) | |Essential Thrombocythemia (ET) | ||
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | |Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN | ||
| Line 97: | Line 101: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| | |[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Primary Myelofibrosis (PMF) | |Primary Myelofibrosis (PMF) | ||
|T. Niroshi Senaratne, UCLA | |T. Niroshi Senaratne, UCLA | ||
| Line 104: | Line 109: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | | |[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING | ||
| || || || ||FQR|| || | |||
|Juvenile Myelomonocytic Leukemia (JMML) | |Juvenile Myelomonocytic Leukemia (JMML) | ||
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | |<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki> | ||
| Line 115: | Line 121: | ||
|FQR has emailed SR several times, last 4/20/22 | |FQR has emailed SR several times, last 4/20/22 | ||
|- | |- | ||
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| | |[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myeloproliferative Neoplasm (MPN), Unclassifiable | |Myeloproliferative Neoplasm (MPN), Unclassifiable | ||
|Thomas Lee, MD, PhD, University of California, Los Angeles | |Thomas Lee, MD, PhD, University of California, Los Angeles | ||
| Line 122: | Line 129: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| | |[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Cutaneous Mastocytosis | |Cutaneous Mastocytosis | ||
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | |S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | ||
| Line 129: | Line 137: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| || | |[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| || | ||
|Systemic Mastocytosis | |Systemic Mastocytosis | ||
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University | |'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University | ||
| Line 136: | Line 144: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| | |[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Mast Cell Sarcoma | |Mast Cell Sarcoma | ||
|Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | |Jordan Lowery, MD and Thuy Phung, MD, PhD Department of Pathology, University of South Alabama, Mobile, AL | ||
| Line 143: | Line 152: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q) | |Myelodysplastic Syndrome (MDS) with Isolated del(5q) | ||
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | |Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG | ||
| Line 150: | Line 160: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 178: | Line 189: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| | |[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic Syndrome (MDS) with Excess Blasts | |Myelodysplastic Syndrome (MDS) with Excess Blasts | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 185: | Line 197: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| | |[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 192: | Line 205: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| | |[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Refractory Cytopenia of Childhood | |Refractory Cytopenia of Childhood | ||
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | |Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG Division of Human Genetics, Cincinnati Children's Hospital Medical Center | ||
| Line 199: | Line 213: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| | |[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Chronic Myelomonocytic Leukemia (CMML) | |Chronic Myelomonocytic Leukemia (CMML) | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
| Line 206: | Line 221: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | |Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative | ||
|Linsheng Zhang, MD, PhD | |Linsheng Zhang, MD, PhD | ||
| Line 213: | Line 229: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | |Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) | ||
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | |Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine | ||
| Line 220: | Line 237: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||PENDING | ||
| || || || ||FQR|| || | |||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
|Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | |Ruth MacKinnon PhD Victorian Cancer Cytogenetics Service Melbourne, Australia | ||
| Line 229: | Line 247: | ||
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | |[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 245: | Line 263: | ||
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 261: | Line 279: | ||
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | |[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 277: | Line 295: | ||
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | |[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 293: | Line 311: | ||
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | |[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 309: | Line 327: | ||
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 325: | Line 343: | ||
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 341: | Line 359: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 373: | Line 391: | ||
|[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | |[[HAEM5:Acute myeloid leukaemia with NPM1 mutation|Acute myeloid leukaemia with NPM1 mutation]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 389: | Line 407: | ||
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | |[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 405: | Line 423: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 437: | Line 455: | ||
|[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | |[[HAEM5:Acute myeloid leukaemia with minimal differentiation|Acute myeloid leukaemia with minimal differentiation]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 453: | Line 471: | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 469: | Line 487: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 485: | Line 503: | ||
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | |[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 501: | Line 519: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 517: | Line 535: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 533: | Line 551: | ||
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | |[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 549: | Line 567: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 565: | Line 583: | ||
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | |[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 600: | Line 618: | ||
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | |[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 616: | Line 634: | ||
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | |[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 632: | Line 650: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 648: | Line 666: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 664: | Line 682: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 680: | Line 698: | ||
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | |[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 763: | Line 781: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | |[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 779: | Line 797: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | |[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 811: | Line 829: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 827: | Line 845: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | |[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 843: | Line 861: | ||
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | |[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 875: | Line 893: | ||
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | |[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 937: | Line 955: | ||
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | |[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 953: | Line 971: | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 969: | Line 987: | ||
|[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | |[[HAEM5:Langerhans cell sarcoma|Langerhans cell sarcoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,081: | Line 1,099: | ||
|[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | |[[HAEM5:Histiocytic sarcoma|Histiocytic sarcoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,191: | Line 1,209: | ||
|[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | |[[HAEM5:KSHV/HHV8-associated multicentric Castleman disease|KSHV/HHV8-associated multicentric Castleman disease]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,207: | Line 1,225: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,223: | Line 1,241: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,239: | Line 1,257: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,255: | Line 1,273: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
|Holli authoring - Complete? Looks like needs more editing of tables | |Holli Drendel authoring - Complete? Looks like needs more editing of tables | ||
| | | | ||
| | | | ||
| Line 1,271: | Line 1,289: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,287: | Line 1,305: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,303: | Line 1,321: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,319: | Line 1,337: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,351: | Line 1,369: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,367: | Line 1,385: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,448: | Line 1,466: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| | |[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING | ||
| || || || ||Shivani Golem (SG) | |||
| || | | || | ||
|Monoclonal B-cell Lymphocytosis | |Monoclonal B-cell Lymphocytosis | ||
| Line 1,468: | Line 1,487: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| | |[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING | ||
| || || || ||SG|| || | |||
|Hairy Cell Leukemia | |Hairy Cell Leukemia | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,475: | Line 1,495: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| | |[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING | ||
| || || || ||SG|| || | |||
|Splenic Marginal Zone Lymphoma | |Splenic Marginal Zone Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,482: | Line 1,503: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| | |[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING | ||
| || || || ||SG|| || | |||
|Splenic Diffuse Red Pulp Small B-cell Lymphoma | |Splenic Diffuse Red Pulp Small B-cell Lymphoma | ||
|Snehal Patel, MD, PhD | |Snehal Patel, MD, PhD | ||
| Line 1,491: | Line 1,513: | ||
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | |[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,507: | Line 1,529: | ||
|[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | |[[HAEM5:Lymphoplasmacytic lymphoma|Lymphoplasmacytic lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,523: | Line 1,545: | ||
|[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | |[[HAEM5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,557: | Line 1,579: | ||
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | |[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,573: | Line 1,595: | ||
|[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | |[[HAEM5:Paediatric nodal marginal zone lymphoma|Paediatric nodal marginal zone lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,621: | Line 1,643: | ||
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | |[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,653: | Line 1,675: | ||
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | |[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,669: | Line 1,691: | ||
|[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | |[[HAEM5:In situ mantle cell neoplasm|In situ mantle cell neoplasm]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,685: | Line 1,707: | ||
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | |[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]] | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 1,731: | Line 1,753: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified | ||
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | ||
| Line 1,745: | Line 1,768: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| | |[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | |High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland | ||
| Line 1,752: | Line 1,776: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| | |[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|ALK-Positive Large B-cell Lymphoma | |ALK-Positive Large B-cell Lymphoma | ||
|Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | |Manando Nakasaki, MD, PhD (University of California, Irvine) Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine) | ||
| Line 1,759: | Line 1,784: | ||
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | |Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23 | ||
|- | |- | ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| | |[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Large B-cell Lymphoma with IRF4 Rearrangement | |Large B-cell Lymphoma with IRF4 Rearrangement | ||
|Afia Hasnain, MBBS, PhD | |Afia Hasnain, MBBS, PhD | ||
| Line 1,766: | Line 1,792: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| | |[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Burkitt-Like Lymphoma with 11q Aberration | |Burkitt-Like Lymphoma with 11q Aberration | ||
|Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |Lauren Shealy, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | ||
| Line 1,794: | Line 1,821: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| | |[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||PENDING | ||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam | |||
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | |Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,808: | Line 1,836: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Plasmablastic Lymphoma | |Plasmablastic Lymphoma | ||
|Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | ||
| Line 1,815: | Line 1,844: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | |(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS | ||
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | |(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital | ||
| Line 1,829: | Line 1,859: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| | |[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Intravascular Large B-cell Lymphoma | |Intravascular Large B-cell Lymphoma | ||
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | |Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy | ||
| Line 1,850: | Line 1,881: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| | |[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||PENDING | ||
| || || || ||GC|| || | |||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | |High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Aiko Otsubo, PhD, Indiana University, Holli Drendel | |Aiko Otsubo, PhD, Indiana University, Holli Drendel | ||
| Line 1,857: | Line 1,889: | ||
| | | | ||
|- | |- | ||
|Burkitt lymphoma||Disease|| | |Burkitt lymphoma||Disease||PENDING | ||
| || || || ||GC|| || | |||
|Burkitt Lymphoma | |Burkitt Lymphoma | ||
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland | |Becky Leung, MBBS (Hons), BSc, Pathology Queensland | ||
| Line 1,922: | Line 1,955: | ||
| | | | ||
|- | |- | ||
|Classic Hodgkin lymphoma||Disease|| | |Classic Hodgkin lymphoma||Disease||PENDING | ||
| || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |||
|GC|| || | |GC|| || | ||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
| Line 1,975: | Line 2,009: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Immunoglobulin-related (AL) amyloidosis||Disease|| | |Immunoglobulin-related (AL) amyloidosis||Disease||PENDING | ||
| || || || ||SG | |||
| || | | || | ||
|Primary Amyloidosis | |Primary Amyloidosis | ||
| Line 1,983: | Line 2,018: | ||
| | | | ||
|- | |- | ||
|Monoclonal immunoglobulin deposition disease||Disease|| | |Monoclonal immunoglobulin deposition disease||Disease||PENDING | ||
| || || || ||SG | |||
| || | | || | ||
|Light Chain and Heavy Chain Deposition Disease | |Light Chain and Heavy Chain Deposition Disease | ||
| Line 1,999: | Line 2,035: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Gamma heavy chain disease||Disease|| | |Gamma heavy chain disease||Disease||PENDING | ||
| || || || ||SG | |||
| || | | || | ||
|Gamma Heavy Chain Disease | |Gamma Heavy Chain Disease | ||
| Line 2,015: | Line 2,052: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Plasmacytoma||Disease|| | |Plasmacytoma||Disease||PENDING | ||
| || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | |||
|SG | |SG | ||
| || | | || | ||
| Line 2,024: | Line 2,062: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Plasma cell myeloma / multiple myeloma||Disease|| | |Plasma cell myeloma / multiple myeloma||Disease||PENDING | ||
| || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG | |||
| || | | || | ||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
| Line 2,032: | Line 2,071: | ||
| | | | ||
|- | |- | ||
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| | |Plasma cell neoplasms with associated paraneoplastic syndrome||Disease||PENDING | ||
| || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | |||
|SG | |SG | ||
| || | | || | ||
| Line 2,102: | Line 2,142: | ||
|Early T-precursor lymphoblastic leukaemia / lymphoma | |Early T-precursor lymphoblastic leukaemia / lymphoma | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||
| Line 2,132: | Line 2,172: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|T-large granular lymphocytic leukaemia||Disease|| | |T-large granular lymphocytic leukaemia||Disease||PENDING | ||
| || || || ||SK|| || | |||
|T-cell Large Granular Lymphocytic Leukemia | |T-cell Large Granular Lymphocytic Leukemia | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,139: | Line 2,180: | ||
| | | | ||
|- | |- | ||
|NK-large granular lymphocytic leukaemia||Disease|| | |NK-large granular lymphocytic leukaemia||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
| Line 2,146: | Line 2,188: | ||
| | | | ||
|- | |- | ||
|Adult T-cell leukaemia/lymphoma||Disease|| | |Adult T-cell leukaemia/lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Adult T-cell Leukemia/Lymphoma | |Adult T-cell Leukemia/Lymphoma | ||
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | |Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG Vanderbilt University Medical Center | ||
| Line 2,153: | Line 2,196: | ||
| | | | ||
|- | |- | ||
|Sezary syndrome||Disease|| | |Sezary syndrome||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
| Line 2,160: | Line 2,204: | ||
| | | | ||
|- | |- | ||
|Aggressive NK-cell leukaemia||Disease|| | |Aggressive NK-cell leukaemia||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Aggressive NK-cell Leukemia | |Aggressive NK-cell Leukemia | ||
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD | |Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
| Line 2,181: | Line 2,226: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Mycosis fungoides||Disease|| | |Mycosis fungoides||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
| Line 2,195: | Line 2,241: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| | |Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
|Theresa Spivey, MD, Shashirekha Shetty, PhD | |Theresa Spivey, MD, Shashirekha Shetty, PhD | ||
| Line 2,230: | Line 2,277: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| | |Indolent T-cell lymphoma of the gastrointestinal tract||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
| Line 2,244: | Line 2,292: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Enteropathy-associated T-cell lymphoma||Disease|| | |Enteropathy-associated T-cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Enteropathy-Associated T-cell Lymphoma | |Enteropathy-Associated T-cell Lymphoma | ||
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | |*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD | ||
| Line 2,251: | Line 2,300: | ||
| | | | ||
|- | |- | ||
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| | |Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | ||
| Line 2,258: | Line 2,308: | ||
| | | | ||
|- | |- | ||
|Intestinal T-cell lymphoma, NOS||Disease|| | |Intestinal T-cell lymphoma, NOS||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | |Derick Okwan MD, PhD (Stanford Medicine, CA) Sumire Kitahara MD (Cedars-Sinai, CA) | ||
| Line 2,265: | Line 2,316: | ||
| | | | ||
|- | |- | ||
|Hepatosplenic T-cell lymphoma||Disease|| | |Hepatosplenic T-cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,272: | Line 2,324: | ||
| | | | ||
|- | |- | ||
|ALK-positive anaplastic large cell lymphoma||Disease|| | |ALK-positive anaplastic large cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
|Miguel Gonzalez Mancera, MD | |Miguel Gonzalez Mancera, MD | ||
| Line 2,283: | Line 2,336: | ||
| | | | ||
|- | |- | ||
|ALK-negative anaplastic large cell lymphoma||Disease|| | |ALK-negative anaplastic large cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | ||
| Line 2,290: | Line 2,344: | ||
| | | | ||
|- | |- | ||
|Breast implant-associated anaplastic large cell lymphoma||Disease|| | |Breast implant-associated anaplastic large cell lymphoma||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
| Line 2,313: | Line 2,368: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease|| | |Nodal TFH cell lymphoma, NOS||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | |Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype | ||
|Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | |Hans Magne Hamnvåg, MD Kamran Mirza, MD, PhD | ||
| Line 2,362: | Line 2,418: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| | |Systemic EBV-positive T-cell lymphoma of childhood||Disease||PENDING | ||
| || || || ||SK|| || | |||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
| Line 2,401: | Line 2,458: | ||
|Follicular dendritic cell sarcoma | |Follicular dendritic cell sarcoma | ||
|Disease | |Disease | ||
| | |PENDING | ||
| | | | ||
| | | | ||